BioSpace News Archive

Innovent Biologics, Inc. announced today that the first patient has been dosed in a phase III clinical trial (ORIENT-15) that is to evaluate Tyvyt® (fully human anti-PD-1 therapeutic monoclonal antibody, generic name: sintilimab injection), in combination with paclitaxel and cisplatin, as first-line treatment in patients with advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Retina specialist and health policy expert to lead nation’s largest association of eye physicians and surgeons

Seven patients, accompanied by reality TV star Ethan Zohn, share their stories about how City of Hope’s compassionate care and innovative treatments composed a new melody of life for them.

Antengene Corporation (Antengene), a clinical stage therapeutics company focused on oncology, announced today that it has completed a $120 million Series B financing.

Technavio analysts forecast the global nebulization masks market to grow at a CAGR of over 6% during the forecast period, according to their latest market research report. The growth momentum of the market is expected to accelerate in the year-over-year growth.